MktsMarkets

ENDRA Life Sciences Inc.
NASDAQ: NDRAKey statistics
NDRA News
Stories mentioning NDRA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 776.00 | 508.00 | 432.00 | 381.00 | 529.00 | 638.00 | 794.00 | 716.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 2,174 | 1,622 | 1,371 | 1,301 | 1,469 | 4,296 | 1,509 | 2,231 |
| Operating Income (Loss) | (2,174) | (1,622) | (1,371) | (1,301) | (1,469) | (4,296) | (1,509) | (2,231) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 42.00 | 13.00 | 24.00 | (764.00) | 66.00 | 2.00 | ||
| Pretax Income | (1,311) | (3,169) | (1,596) | (1,226) | (1,036) | (4,149) | (2,354) | (2,229) |
| Tax Provision | 0.00 | 0.00 | 0.00 | |||||
| Net Income (Loss) | (1,311) | (3,169) | (1,596) | (1,226) | (1,036) | (4,149) | (2,354) | (2,229) |
| Earnings Per Share (Basic) | (1.09) | (2.10) | (1.86) | (9.54) | ||||
| Earnings Per Share (Diluted) | (1.09) | (2.10) | (1.86) | (9.54) | ||||
| Weighted Average Shares Outstanding (Basic) | 1,200 | 761.00 | 558.00 | 247.00 | ||||
| Weighted Average Shares Outstanding (Diluted) | 1,200 | 761.00 | 558.00 | 247.00 | ||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NDRA
ENDRA Life Sciences Inc. (NASDAQ: NDRA) is a stock listed on the Nasdaq Stock Market under the ticker symbol NDRA. It last traded at $4.80 (Oct 27, 2026, 9:31 AM ET), down 0.4% on the day. That gives ENDRA Life Sciences a market capitalisation of $7.3M.
Over the past 52 weeks NDRA has traded between $2.96 and $6.95.
For the quarter ended Mar 31, 2026 it reported a net loss of $1.3M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$1.3M |
| Dec 31, 2025 | — | -$3.2M |
| Sep 30, 2025 | — | -$1.6M |
| Jun 30, 2025 | — | -$1.2M |
From ENDRA Life Sciences’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…